Original scientific paper

https://doi.org/10.11613/BM.2019.020707

Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study

Sara Tartaglione ; Department of Molecular Medicine, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Irene Pecorella ; Department of Radiological Sciences, Oncology and Anatomical Pathology, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Serena Rita Zarrillo orcid.org/0000-0001-5670-1592 ; Department of Molecular Medicine, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Teresa Granato ; CNR-IBPM, National Research Council, Rome, Italy
Valentina Viggiani ; Department of Molecular Medicine, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Lucia Manganaro ; Department of Radiological Sciences, Oncology and Anatomical Pathology, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Cinzia Marchese ; Department of Experimental Medicine, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Antonio Angeloni ; Department of Experimental Medicine, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy
Emanuela Anastasi orcid.org/0000-0002-5124-3219 ; Department of Molecular Medicine, Policlinico Umberto I, University of Rome “Sapienza”, Rome, Italy

Abstract

Introduction: Protein induced by vitamin K absence II (PIVKA-II) is an abnormal prothrombin increased in gastrointestinal malignancy. We aimed to evaluate PIVKA-II in comparison to established pancreatic cancer (PC) biomarkers (CA 19-9, carcinoembryonic antigen (CEA) and CA 242) measured in PC patients and in patients with benign pancreatic diseases.
Materials and methods: We studied 26 PC patients (Group 1) and 20 patients with benign pancreatic diseases (Group 2). PIVKA-II and CEA were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Gent, Belgium), CA 19-9 and CA 242 were measured by ELSA (CisBio Bioassays, Codolet, France) and EIA (Fujirebio Diagnostics AB, Göteborg, Sweden), respectively. Receiver operating characteristic (ROC) analysis was performed to assess biomarkers’ diagnostic characteristics in both groups.
Results: Median and interquartile range (IQR) in Group 1 and Group 2 were: 1749.0 (320.2 – 3921.0) vs. 31.0 (23.0 – 43.0) mAU/mL (P < 0.001) for PIVKA-II, 260.0 (158.7 – 272.0) vs. 45.2 (9.0 – 58.0) U/mL (P = 0.034) for CA 19-9, 104.0 (30.2 – 150.0) vs. 7.2 (4.8 – 26.0) U/mL (P < 0.050) for CA 242, 9.4 (5.3 – 37.5) vs. 4.5 (1.8 – 7.0) ng/mL (P = 0.021) for CEA. Areas under the ROC curve of PIVKA-II, CA 19-9, CA 242, CEA were 0.86 (95% CI: 0.71 – 1.00), 0.58 (95% CI: 0.38 – 0.78), 0.73 (95% CI: 0.54 – 0.92), 0.64 (95% CI: 0.44 – 0.85), respectively.
Conclusions: PIVKA-II is significantly higher in PC than in benign pancreatic diseases. PIVKA-II shows a rather good diagnostic performance compared to CA 19-9, CEA and CA242, thus its determination could help PC management.

Keywords

pancreatic cancer; PIVKA-II; CA 19-9; CA 242; CEA

Hrčak ID:

221079

URI

https://hrcak.srce.hr/221079

Publication date:

15.6.2019.

Visits: 1.383 *